Navigation Links
ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR

>

About ZIO-101

ZIO-101 is a proprietary small molecule organic arsenic licensed from The University of Texas M. D. Anderson Cancer Center and Texas A&M University. ZIO-101 induces cell cycle arrest and cell death by targeting several cellular pathways essential for cell survival. Exposure to ZIO-101 has a direct as well as indirect effect on mitochondrial functions, resulting in depletion of energy supply to the cell and induction of apoptosis (programmed cell death). Increase in intra-cellular Reactive Oxygen Species enhances this effect on mitochondrial functions and consequently the activation of the signal transduction pathway leading to apoptosis. In addition, ZIO-101 interrupts the cell cycle at the G2/M phase of tumor cells inducing cell death through this pathway as well.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its prod
'"/>




Page: 1 2 3

Related medicine technology :

1. ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
3. ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR
4. ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ZIOPHARM Presents Data Highlighting Oral ZIO AACR
(Date:5/19/2008)... May 19 /- Helix Health, the first U....ng a 90-minute webcast this,Wednesday, May 21, 200... Medicine Is Changing the Management of Breast & O...re, http://event.netbriefings.com/event/helixhealt... United States are diagnosed with cancer.,There is...
(Date:5/19/2008)...Be Presented at the 2008 Annual European Congress ...Against Rheumatism (EULAR) -, - Initiation of Pha... of 2008 -, SAN D...iences, Inc.,(Nasdaq: RDEA ) today announced the ...or the treatment of patients with gout, RDEA594. G...
(Date:5/19/2008)...egulatory equivalent filing anticipated in 1Q 2009.../ -- Pharmasset, Inc.,(Nasdaq: VRUS ) has nominat...e treatment of chronic hepatitis C virus (HCV). PS...rase inhibitor of HCV that is being advanced into,...dies required for,submission of an Investigational...
(Date:5/18/2008)...ve Disease Week data highlight effects of AMITIZA ...SAN DIEGO, May 18 /- New study result...ostone) 8 mcg lead to significant relief,of overal...pation (IBS-C).,These results were presented at Di...l international meeting of digestive disease speci...
Breaking Medicine Technology:Join NPR's David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 2Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 3New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 2New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 3New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 4New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 5New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 6New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 7Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control 26 Sexual Function in Women 657 1Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control 26 Sexual Function in Women 657 2Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control 26 Sexual Function in Women 657 3Scientists discover tiny RNAs play a big role in controlling genes 4578 1Food restriction increases dopamine receptor levels in obese rats 4575 1Food restriction increases dopamine receptor levels in obese rats 4575 2Food restriction increases dopamine receptor levels in obese rats 4575 3The new source of islet cells 4571 1
...NCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Cyto...ta from a Phase 1,dose escalation study evaluating...n) in combination with bortezomib (Velcade(R),Mil...lapsed,multiple myeloma. Data from 33 patients wer...al of Bortezomib (Vel) and Samarium,(Sam) in Multi...
..., Greece--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHARM...e presentation of two,posters at the XIth Annual I...reece from June 25-28th, 2007. The meeting highlig...atment of multiple,myeloma. ZIOPHARM is presenting...data that further elucidates its unique,mechanism ...
Other Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 2ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 3ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 4
(Date:5/20/2008)...e/ -- Ambulatory Services of,America, Inc. announc...h,joint venture to provide outpatient radiation on... between Denton Cancer Center, LP and ASA,s,subsid... ROSA of Denton,will own and operate a radiation t...ly owned and operated by Denton Cancer Center., (...
(Date:5/20/2008)...ng new out-patient procedures at no ... Calif., May 20 /PRNewswire/ -- Compass Clinical R... San Francisco Bay Area (RSC) are,hoping to recrui...nx, a,build-up of fluid in the fallopian tubes tha... as a part of a study of the effectiveness of a ne...
(Date:5/20/2008)...turated Fat - and with Omega-3, PARAMUS, N.J., Ma...(Nasdaq: SMBL ) has launched Smart Balance(R) But...utter Blend Sticks are 50 percent real butter,and ...art Balance(R) Butter,Blend Sticks are offered in ...or a healthier and tasty alternative for use in co...
(Date:5/20/2008)...ery or survival, researchers say. , , T...y dialysis for patients with acute kidney injury d...reduce the rate of organ failure, a new study find...n seen in critically ill patients. Approximately 2...d 35 percent of critically ill patients, will suff...
Breaking Medicine News(10 mins):Health News:Ambulatory Services of America, Inc. Announces Joint Venture With Denton Cancer Center, LP 2Health News:Research Grant to Fund Free Surgeries for Women Suffering From Blocked Fallopian Tubes 2Health News:Research Grant to Fund Free Surgeries for Women Suffering From Blocked Fallopian Tubes 3Health News:New Smart Balance(R) Butter Blend Sticks Make Healthier Cooking & Baking Easy 2Health News:More Dialysis Not Better in Acute Kidney Injury 2
...es produced by the hypothalamus, the area of the b... and body temperature, may underlie chronic migrai... the general population who suffer from the debili... hormones could prevent or reduce the severity of ...
...inistration has approved a new drug for treating o...erioration in the cartilage of certain joints. Unl...toimmune disease, osteoarthritis results from over...of strenuous sports, obesity or aging. Pharmacia C...
...e Warren Grant Magnuson Clinical Center shows that...cook" tumors without actually removing them. The n...y and liver cancers, can also be used on cancers e... radiofrequency ablation (RFA), a tiny needle is i...
...ferred the launch of 'Disprin CV' (cardiovascular)...painkiller 'Disprin Plus', the company's Regional ... announced a change in the brand-name 'Disprin Plu...unch of Disprin Plus, there were reports citing in...
Other Medicine News:
...ists steerable guidewires across difficult lesions...eter offers a low profile (3F-4F) and is compatibl... crossing difficult occlusions. Once the occlusio...guidewire position and an angioplasty balloon is d...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system.
The new XVG catheter is our highest power thrombectomy catheter designed for accessing distal anatomy. Utilizing proprietary Cross-Stream water jet technology, the XVG catheter removes thrombus quick
...copic navigation system that tracks multiple intra...d Wittkampf, Ph.D., and is being developed by Surg...,The LocaLisa system uses three skin electrode p...art to track catheters. Using a reference electrod...
Medicine Products: